ONC-392,Pembrolizumab
biontech,Merck
['sclc', 'nsclc', '$bntx', 'biontech']
$bntx [15s. delayed]: issued press release on june 02, 06:45:00: biontech and oncoc4 present positive phase 1/2 data for antibody candidate bnt316/onc-392 in hard-to-treat nsclc at asco 
Flash Alert is a low-latency financial news service which sources SEC, press releases, credible news sources to get your news about stocks in near real-time